Bioverativ USA, Inc.

← The SEC Ephemeris: the whole map

Bioverativ USA, Inc. sutimlimab

In the graph: all 1 documents (2 pages).

Application: BLA 761164
Ticker: Bioverativ USA, Inc.
Product: sutimlimab
Disease area: Not yet classified
Response path: Not yet classified
Complete Response Letters: November 13, 2020

From FDA letters and SEC filings. Not investment or medical advice.

Not yet classified

ARS Pharmaceuticals, Inc. Neffy
Ascelia Pharma AB
Ascendis Pharma Bone Diseases A/S palopegteriparatide
Astellas Pharma US, Inc. IZERVAY
AstraZeneca AB Breztri Aerosphere
AstraZeneca Pharmaceuticals LP anifrolumab
Atara Biotherapeutics, Inc. tabelecleucel®) @)
AuroMedics Pharma LLC Cyclophosphamide
AVEO Pharmaceuticals, Inc. tivozanib hydrochloride
Azurity Pharmaceuticals, Inc. sitagliptin
B. Braun Medical, Inc. Acetaminophen
Bausch Health Ireland Limited fluorescein sodium
Baxter Healthcare Corporation DAPZURA RT
Bayer HealthCare LLC Naproxen sodium
Belcher Pharmaceuticals, LLC. Ablysinol
BendaRx USA Corporation bendamustine
Bio-Thera Solutions Ltd. BAT1706
Biogen, Inc.
Biohaven Therapeutics, Ltd. troriluzole
Bioprojet Pharma Wakix
Bioverativ USA, Inc. sutimlimab
Botanix SB Inc. sofpironium bromide
Braeburn Inc. BRIXADI
Braeburn Pharmaceuticals Inc. BRIXADI
Braintree Laboratories, Inc. Suflave
Bridge Regulatory Affairs, LLC octreotide hydrochloride extended- release
Bristol-Myers Squibb dapagliflozin
Cadence Pharmaceuticals Ofirmev
Camargo Pharmaceutical Services Mycapssa
Capricor, Inc. deramiocel
Celitrion, Inc. CT-P17
CellTrans Inc. Donislecel manufactured at your Chicago
CELLTRION, Inc. Steqeyma
Checkpoint Therapeutics, Incorporated cosibelimab
Chelsea Therapeutics, Inc. NORTHERA
Chemo Research, S.L. dienogest
Chiesi USA, Inc. PRX-102
Cingulate Therapeutics, LLC dexmethylphenidate hydrochloride
Cipla USA, Inc.
Citius Pharmaceuticals, Inc. Lymphir

All 283 on the full map →

Group by

Build queue · replay at pipeline speed